Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Law

Pulmonary Disease Orange, CA Medical Doctor

NPI 1861460370 CMS profile 130079

1010 W La Veta Ave, Ste 750, Orange, CA 92868

Open in the dashboard

General payments

$3,194

172 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Law of Orange, CA is reported in the CMS Open Payments database as having received $3,194 across 172 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $122 1
2023 General $708 36
2022 General $292 15
2021 General $637 30
2020 General $627 34
2019 General $808 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Law
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to James Law were reported at $122. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year James Law Pulmonary Disease median Middle half National median
2019 $808 $377 $109–$1,340 $163
2020 $627 $230 $56–$907 $114
2021 $637 $269 $68–$1,072 $132
2022 $292 $390 $100–$1,457 $149
2023 $708 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $122 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $648 43 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $466 20 payments
  3. Genentech USA, Inc. $245 17 payments
  4. AstraZeneca Pharmaceuticals LP $197 6 payments
  5. Novo Nordisk Inc $180 10 payments
  6. Janssen Pharmaceuticals, Inc $161 9 payments
  7. AbbVie, Inc. $115 5 payments
  8. Lilly USA, LLC $111 6 payments
  9. Pfizer Inc. $102 6 payments
  10. Abbott Laboratories $96 1 payment
  11. Other $874 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,179 171 payments
  2. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. OFEV $420 18 payments
  2. TRELEGY ELLIPTA $354 22 payments
  3. Esbriet $245 17 payments
  4. XARELTO $161 9 payments
  5. Ozempic $157 9 payments
  6. RYBELSUS $157 9 payments
  7. TEZSPIRE $122 1 payment
  8. Xolair $117 14 payments
  9. Confirm Rx $96 1 payment
  10. HETLIOZ $93 5 payments
  11. Other $2,102 123 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

1,214

Median for Internal Medicine: 777

Drug cost

$104,012

Median for Internal Medicine: $73,373

Branded share of claims

18.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 42 $45,034
Eliquis Apixaban Brand 22 $19,817
Breo Ellipta Fluticasone/Vilanterol Brand 34 $19,456
Wixela Inhub Fluticasone Propion/Salmeterol Brand 12 $3,650
Albuterol Sulfate Hfa Albuterol Sulfate Brand 40 $1,763
Levothyroxine Sodium Generic 94 $1,581
Atorvastatin Calcium Generic 137 $1,529
Rosuvastatin Calcium Generic 72 $1,179
Losartan Potassium Generic 86 $1,026
Omeprazole Generic 71 $1,021

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

172 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record